Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice

Hypertension Research

Volumn 31, Issue 1, 2008, Pages 161-168

  Iwai, Masaru ^a   Inaba, Shinji ^a   Tomono, Yumiko ^a   Kanno, Harumi ^a   Iwanami, Jun ^a   Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Atherosclerosis; Cerebral ischemia; Oxidative stress; Receptors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; CHOLESTEROL; FAT DROPLET; SUPEROXIDE; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTERY WALL; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; HISTOPATHOLOGY; KNOCKOUT MOUSE; LIPID STORAGE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OXIDATIVE STRESS; RECEPTOR BLOCKING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZIMIDAZOLES; BENZOATES; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MICE; MICE, KNOCKOUT; SUPEROXIDES;

EID: 40149094470     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.161     Document Type: Article

References (33)

1. Spagnoli LG, Mauriello A, Sangiorgi G, et al: Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004; 292: 1845-1852.
2. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
3. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al: Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657-663.
4. Walther T, Olah L, Harms C, et al: Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16: 169-176.
5. Iwai M, Liu H-W, Chen R, et al: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843-848.
6. 1 receptor antagonists in the brain. Cell Mol Neurobiol 2006; 26: 1099-1111.
7. 1 antagonist. Stroke 2002; 33: 2297-2303.
8. 1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545-551.
9. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G: Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062-3067.
10. Iwai M, Chen R, Li Z, et al: Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005; 112: 1636-1643.
11. Hata R, Mies G, Wiessner C, et al: A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 1998; 18: 367-375.
12. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-1885.
13. Connolly ES Jr, Winfree CJ, Springer TA, et al: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-216.
14. Tabrizi P, Wang L, Seeds N, et al: Tissue plasminogcn activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999; 19: 2801-2806.
15. Szocs K, Lassegue B, Sorescu D, et al: Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22: 21-27.
16. Biswas SK, Newby DE, Rahman I, Megson IL: Depressed glutathione synthesis precedes oxidative stress and atherogenesis in Apo-E(-/-) mice. Biochem Biophys Res Commun 2005; 338: 1368-1373.
17. Guzik TJ, Sadowski J, Guzik B, et al: Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 333-339.
18. Yoshii T, Iwai M, Li Z, et al: Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29: 457-466.
19. Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
20. Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
21. Schiffrin EL: Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study. Curr Hypertens Rep 2002; 4: 39-40.
22. Jöhren O, Imboden H, Häuser W, Maye I, Sanvitto GL, Saavedra JM: Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997; 757: 218-227.
23. Tamura K, Yokoyama N, Sumida Y, et al: Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knock-out mice. J Endocrinol 1999; 160: 401-408.
24. Davisson RL, Yang G, Beltz TG, Cassell MD, Johnson AK, Sigmund CD: The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res 1998; 83: 1047-1058.
25. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD: Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 2000; 106: 103-106.
26. 2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 2003; 284: H116-H121.
27. Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261.
28. Vitale C, Mercuro G, Castiglioni C, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
29. Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated r eceptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452.
30. Derosa G, Cicero AFG, D'Angelo A, et al: Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens Res 2006; 29: 849-856.
31. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43:993-1002.
32. Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 2005; 42 (Suppl 1): S9-S16.
33. Luo Y, Yin W, Signore AP, et al: Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435-448.